|
US2020360300A1
|
|
Suppression of Cytokine Release and Cytokine Storm
|
|
US2019320975A1
|
|
Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
|
|
TW202019404A
|
|
Novel lipids
|
|
TW201946613A
|
|
Dosing regimens for treatment of proliferative disorders
|
|
KR20200072479A
|
|
Protective effects of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC on drugs causing channel disease
|
|
US2019008878A1
|
|
Compositions and method for reducing cardiotoxicity
|
|
WO2018089687A1
|
|
Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies
|
|
US2018055770A1
|
|
Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
|
|
CA3039596A1
|
|
Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies
|
|
US2017312366A1
|
|
Prevention of drug-induced atrio-ventricular block
|
|
WO2017151360A1
|
|
Sphingosine kinase inhibitors and ceramide for maintenance therapy of glioblastoma
|
|
US2017119802A1
|
|
Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
|
|
US2017095489A1
|
|
Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
|
|
US2017035887A1
|
|
Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
|
|
CA2940470A1
|
|
Treatment for glioblastoma
|
|
US2016287532A1
|
|
Curcumin for treating intervertebral disc disease
|
|
US2016184330A1
|
|
Suppression of cytokine release and cytokine storm
|
|
EP3082768A1
|
|
Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
|
|
EP3071190A1
|
|
Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
|
|
CA2929699A1
|
|
Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
|
